Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 
Examine the cost-effectiveness of SROM, hydromorphone, diacetylmorphine, and fentanyl in opioid use disorder, and describe the evidence-based guidelines for the use of these treatments
Lit review | 2021
Clinical guidance, Evidence base, Safer supply, About prescribers, Substitution/OAT
To present the 2021 update of the Wound Bed Preparation paradigm
Guidelines | 2021
Clinical guidance, Wrap-around services, About prescribers, Chronic pain, Injecting drugs
Guide or handbook | 2021
Overdose, Clinical guidance, Harm reduction, About prescribers, Social services, Illegal drugs, SCS/OPS
Research has shown that the vast majority of individuals who experience problems with opioid misuse and addiction have current or past experiences of trauma and violence.
Guide or handbook | 2018
Clinical guidance, Harm reduction, Sex/Gender , Mental health
Alcohol and other drug (AOD) workers from a variety of service settings are now frequently required to respond to methamphetamine users who are experiencing the harmful effects of methamphetamine, goi
Guide or handbook | 2008
Clinical guidance, Harm reduction, About prescribers, Social services, Illegal drugs, Stimulants, Transitions in care/treatment
Guidelines | 2020
Clinical guidance, Harm reduction, Safer supply, About prescribers, Substitution/OAT, Transitions in care/treatment
The aim of this work was to understand (1) the perspectives of family physicians (FPs) as it relates to opioid prescribing, and (2) the perceived barriers and enablers to guideline-adherent opioid pre
Original research | 2019
Clinical guidance, Policy/Regulatory, Hesitancy of prescribers , Safer supply, About prescribers, Barriers and enablers, Chronic pain
Short visual summary of Blood Ties' "Don't Be An A**hole" best practices report
Infographic | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma
Outlines key themes found among people who use drugs about their experiences with various health and social service agencies and providers in Whitehorse
Report | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma
Guidelines | 2020
Clinical guidance, About pharmacists, About prescribers
Pharmacists Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About pharmacists, Stimulants, Substitution/OAT, Injecting drugs
Prescriber Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Injecting drugs
Very little is known about the value of UDS, the optimum screening frequency in general, or its specific use for buprenorphine treatment in primary care.
Original research | 2021
Clinical guidance, About prescribers, Outcomes, Substitution/OAT, Diversion
Guidelines | 2021
Clinical guidance, About prescribers, Chronic pain
Provide clinical guidance to ensure the uninterrupted access to OAT medications for patients during the COVID-19 pandemic.
Guidelines | 2020
Clinical guidance, Harm reduction, About pharmacists, About prescribers
Commentary | 2021
Clinical guidance, Harm reduction, Hesitancy of prescribers , Safer supply, About pharmacists
Describes a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this in
Original research | 2019
Clinical guidance, Evidence base, Harm reduction, Safer supply, About prescribers, Outcomes, Substitution/OAT, Injecting drugs
To raise awareness of alternative techniques that can facilitate buprenorphine-naloxone treatment for opioid use disorder.
Original research | 2020
Clinical guidance, Harm reduction, About prescribers, Substitution/OAT
Shared decision-making (SDM) is an approach to clinical decision-making that includes patients' values and preferences during health-related decisions.
Scoping review | 2021
Clinical guidance, About prescribers, About PWUD
We conducted a scoping review of feasibility studies reporting on preferred SCS design characteristics, staffing models and ancillary services.
Scoping review | 2021
Overdose, Clinical guidance, About prescribers, About PWUD, Illegal drugs, SCS/OPS

Affiner votre recherche

Mots clés
Format
Région